Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Abroad (travel likely)RecruitingPHASE2

Conditions

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 · Lymphoblastic Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Contact: Study coordinator (Ryan Cassaday, MD) · cassaday@uw.edu · 206-606-6744
Contact: Principal Investigator (Ryan Cassaday, MD)

Study leads

Ryan Cassaday, MD
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative · Burkitt-Like Lymphoma With 11q Aberration

Abroad (travel likely)RecruitingPHASE1, PHASE2

Houston, United States

Personalized NK Cell Therapy in CBT

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Biphenotypic Leukemia · Acute Lymphoblastic Leukemia

Abroad (travel likely)RecruitingPHASE2

Houston, United States

Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Abroad (travel likely)RecruitingPHASE1

Duarte, United States